Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Bausch & Lomb Incorporated
Deal Size : $485.0 million
Deal Type : Collaboration
City Therapeutics, Bausch + Lomb Partner on Preclinical RNAi Eye Drug
Details : The collaboration aims on the development of a novel RNAi-based therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Bausch & Lomb Incorporated
Deal Size : $485.0 million
Deal Type : Collaboration